Xcout Intel
Oblenio Bio competitors & alternatives
The 12 closest competitors and alternatives to Oblenio Bio among biotechnology companies — ranked by similarity to what Oblenio Bio actually does, not by market-cap band.
Subscribe to see Oblenio Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Oblenio Bio
Oblenio Bio is a biotechnology research company headquartered in Lexington, Massachusetts, focused on transforming the treatment of refractory autoimmune diseases by delivering a broad immune system reset.
Oblenio Bio at a glance
Oblenio Bio is a biotechnology company headquartered in United States. It has raised at least $62M across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round, Series A, raised $62M in June 2026. Xcout tracks 8 named people at Oblenio Bio, including Samantha Truex (Chief Executive Officer).
Oblenio Bio leadership
- Samantha TruexChief Executive Officer
- Tapan ManiarChief Medical Officer
- Rohan LathiaSVP Corporate Development and Strategy
- Iris CheongVice President, Controller
- Sara BurkeVice President, Program Lead
- Tara BarreiraVice President, Technical Operations
2 more named people on record for Oblenio Bio, with roles, board committees and tenure — see the full roster →
Oblenio Bio funding rounds
At least $62M raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $62M | 5 named | |
| — | Undisclosed | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Oblenio Bio competitors
Ranked by semantic similarity — how close each company is to Oblenio Bio by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Zag Bio is a biotechnology research company headquartered in Cambridge, Massachusetts. The enterprise focuses on developing innovative therapies for autoimmune diseases by targeting the thymus gland to engage the body's natural T cell central tolerance mechanisms.
Similar biotechnology company
Ouro Medicines is a biotechnology company headquartered in South San Francisco, California, developing immune reset therapeutics for chronic immune-mediated diseases.
Similar biotechnology company
Abcuro, Inc. is a biotechnology company headquartered in Newton, Massachusetts, focused on developing advanced immunotherapies to treat autoimmune diseases and cancer.
Similar biotechnology company
Agenus Inc. is a biotechnology company headquartered in Lexington, Massachusetts, focused on the discovery and development of better immunotherapies and cancer treatments.
Similar biotechnology company
Kanyos Bio, Inc. is a biotechnology company located in Cambridge, Massachusetts, created as a subsidiary of Anokion SA to develop clinical candidates for immune tolerance.
Similar biotechnology company
AbolerIS Pharma is a pre-clinical stage biotech company founded in Nantes, France, specializing in the development of innovative immunomodulators and advanced biopharmaceuticals for autoimmune conditions.
Biotech
HiFiBio Therapeutics is a clinical-stage immune modulation biotechnology company headquartered in Cambridge, Massachusetts. The company focuses on discovering and developing novel precision antibody therapeutics for immunology and oncology applications.
Similar biotechnology company
TRex Bio, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on discovering and developing precision therapeutics to treat moderate-to-severe immune-mediated diseases by targeting regulatory T cells.
Similar biotechnology company
AviSia Therapeutics is a clinical-stage biotechnology company headquartered in Amsterdam, Netherlands, pioneering antigen-specific immunotherapies for autoimmune diseases. Established as a spin-off, the company develops targeted treatments to reprogram immune responses.
Biotech
Repertoire Immune Medicines is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The firm works to unlock and direct the power of the human immune system to develop novel therapeutics and medicines.
Biotech
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Biotech
Tr1X is a private, clinical-stage biotechnology company focused on developing regulatory T cell-based products for autoimmune and inflammatory diseases. The company aims to advance Tr1-based immunotherapies to address unmet medical needs and is headquartered in San Diego, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Oblenio Bio and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Oblenio Bioand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →